FDA approves daraxonrasib as RASONQUE for metastatic pancreatic adenocarcinoma

On 26 August 2026, the U.S. Food and Drug Administration approved daraxonrasib—previously widely known as RMC-6236—under the brand name RASONQUE.

What the FDA approved

The FDA notice identifies RASONQUE (daraxonrasib), from Revolution Medicines, Inc., as an inhibitor of the RAS GTPase family. The approved population is adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

The official FDA notice and current prescribing information—not a supplier website—are the appropriate sources for the full indication, dosing, warnings, adverse reactions and other clinical details.

Why RMC-6236 appears in earlier research

RMC-6236 is the development code used across early mechanistic studies, clinical-trial registrations and the phase 1–2 program. Daraxonrasib is the generic name; RASONQUE is the brand of the finished medicine. These names connect the history of one active compound but serve different communication and regulatory purposes.

The pivotal evidence

RASolute 302 (NCT06625320) was an international, randomized, open-label phase 3 study in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. The peer-reviewed publication concluded that daraxonrasib led to significantly longer overall survival and progression-free survival than investigator-selected chemotherapy in the trial population.

What the approval does not mean

It does not make chemical research material, bulk active ingredient or an analytical reference interchangeable with the FDA-approved finished drug. RASONQUE has a defined manufacturer, formulation, labeling and regulated supply chain.

Practical terminology

This article is educational and does not provide medical advice. Clinical questions should be directed to a licensed healthcare professional and the current FDA-approved prescribing information.